Similar effects on caspase 3 activation were observed when RANKL signalling was inhibited with either SPD304 or RANKL nAb upon treatment of melanoma cells with osteoblast CM (Figure 5d) and conversely, treatment of melanoma cells with RANKL attenuated BRAFi induced caspase 3 activation (Figure S5b). The gene discussed is CASP3; the disease is melanoma.